A number of trials combining PARP and CTLA-4 inhibitors are currently underway, including a phase I trial of thoracic radiation combined with durvalumab +/− tremelimumab or olaparib in ES-SCLC after first-line chemotherapy (NCT03923270) [67]. This evidence concerns the gene PARP1 and small cell lung carcinoma.